<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512210</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5360</org_study_id>
    <secondary_id>UM1AI068636</secondary_id>
    <nct_id>NCT03512210</nct_id>
  </id_info>
  <brief_title>Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection</brief_title>
  <acronym>MINMON</acronym>
  <official_title>A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To achieve global hepatitis C virus (HCV) elimination by 2030, 80% of the ~71 million people&#xD;
      with chronic HCV infection will need to be treated, necessitating simplification of treatment&#xD;
      delivery and associated laboratory monitoring without compromising efficacy or safety. The&#xD;
      COVID-19 pandemic has further highlighted the need for innovative models of health care&#xD;
      delivery that minimize face-to-face patient-provider contact. The purpose of this study was&#xD;
      to evaluate the feasibility, safety, and efficacy of a minimal monitoring (MINMON) strategy&#xD;
      to deliver interferon- and RBV-free, pan-genotypic DAA therapy to treat active HCV in HCV&#xD;
      treatment naïve participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluated the feasibility, safety, and efficacy of a minimal monitoring (MINMON)&#xD;
      strategy of delivering interferon- and ribavirin (RBV)-free, pan-genotypic direct-acting&#xD;
      antiviral (DAA) therapy to treat active hepatitis C virus (HCV) in HCV treatment naïve&#xD;
      participants, with or without HIV-1 co-infection, and with no evidence of decompensated&#xD;
      cirrhosis.&#xD;
&#xD;
      The MINMON intervention included four components: 1) No pre-treatment HCV genotyping; 2)&#xD;
      Entire 12-week treatment course (84 tablets) dispensed to participants at study entry; 3) No&#xD;
      scheduled on-treatment laboratory monitoring or clinic visits prior to SVR evaluation&#xD;
      scheduled 24 weeks following entry; 4) Remote contact with participants at week 4 for&#xD;
      adherence counseling and locator update, and week 22 for scheduling of SVR visit and locator&#xD;
      update.&#xD;
&#xD;
      At study entry, all participants received a single-tablet, fixed-dose combination (FDC) of&#xD;
      sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks.&#xD;
&#xD;
      The trial was designed to accrue 400 adult participants who may be co-infected with HIV-1&#xD;
      (limited to no more than 200 participants), and whose liver disease state is either no&#xD;
      cirrhosis (defined by Fibrosis-4 score) or compensated cirrhosis (defined by Fibrosis-4 and&#xD;
      Child-Turcotte-Pugh (CTP) scores, and limited to no more than 80 participants). Accrual from&#xD;
      research sites in the United States was limited to no more than 132 participants.&#xD;
&#xD;
      The study proceeded in two steps: Step 1: MINMON intervention and Step 2: post-MINMON follow&#xD;
      up.&#xD;
&#xD;
      During Step 1 (MINMON intervention), participants were contacted remotely at week 4 to&#xD;
      inquire about study medication adherence and confirm locator information, and again at week&#xD;
      22 to schedule the sustained virologic response (SVR) evaluation and confirm locator&#xD;
      information. Unplanned in-person clinic visits before week 22 were permissible to address&#xD;
      common treatment toxicities that could not be managed remotely. The primary efficacy outcome&#xD;
      measure, sustained virologic response (SVR), was evaluated starting at the week 24 study&#xD;
      visit. Early discontinuation of treatment did not alter the timing of the SVR evaluation. If&#xD;
      the week 24 visit was missed, SVR could be evaluated at any time up to 76 weeks following&#xD;
      study entry.&#xD;
&#xD;
      Following SVR evaluation, participants entered Step 2 for two additional post-SVR evaluation&#xD;
      study visits at weeks 48 and 72. Participants were contacted remotely at weeks 42 and 68 to&#xD;
      schedule such visits. The schedule of additional post-MINMON evaluation visits were dependent&#xD;
      on the week of Step 2 entry.&#xD;
&#xD;
      In version 1 of the study, total study duration was up to 76 weeks. Due to the COVID-19&#xD;
      Pandemic, the window of the week 72 visit was extended for participants who completed SVR&#xD;
      evaluations and registered to Step 2 to October 31, 2020 for US sites and to February 28,&#xD;
      2021 for non-US sites. This extension did not alter the window for SVR evaluation.&#xD;
&#xD;
      All scheduled in-clinic study visits included a physical exam, blood collection, and&#xD;
      collection of plasma samples. For participants able to become pregnant, pregnancy testing was&#xD;
      conducted at screening, entry, and at any in-clinic visit during Step 1 if pregnancy was&#xD;
      suspected. Liver Elastography was an optional evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response 12 (SVR12)</measure>
    <time_frame>From at least 22 weeks and up to 76 weeks from treatment initiation</time_frame>
    <description>SVR12 was defined as plasma HCV RNA less than the lower limit of quantification (LLOQ) from the earliest sample drawn at least 22 weeks following study treatment initiation (i.e. at a visit scheduled at least 10 weeks after scheduled end of study treatment). Participants without any HCV RNA result at least 22 weeks after treatment initiation will be considered as having HCV RNA greater than the LLOQ.&#xD;
LLOQ was defined as &lt;15 IU/mL for results tested at USA centralized testing laboratory Quest using the &quot;Roche COBAS® HCV Quantitative nucleic acid test for use on the COBAS® 6800/8800&quot; assays for quantitation (and detection) of HCV, and &lt;12 IU/mL for results tested at regional international labs using &quot;Abbott RealTime HCV&quot; assay for quantitation (and detection) of HCV.&#xD;
A two-sided 95%, confidence interval was calculated for this percentage using the Wilson (score) method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With an Occurrence of Serious Adverse Events According to International Council for Harmonization (ICH) Criteria</measure>
    <time_frame>From treatment initiation to 28 weeks</time_frame>
    <description>Serious adverse events (SAEs) as defined by ICH guidelines.&#xD;
A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Unplanned Clinic Visit Prior to SVR12 Evaluation</measure>
    <time_frame>From treatment initiation to 22 weeks</time_frame>
    <description>According to the study minimal monitoring intervention, there were no planned clinic visits prior to study week 24, when SVR12 was scheduled to be evaluated. An unplanned clinic visit was defined as an in-clinic visit occurring from treatment initiation to up to week 22.&#xD;
A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Occurrence of One or More Non-serious, Grade &gt;= 3 Adverse Event (AE), or Treatment Limiting AE.</measure>
    <time_frame>From treatment initiation to 28 weeks</time_frame>
    <description>AEs included all primary diagnoses, primary signs/symptoms, and primary laboratory abnormalities that either had severity grade ≥ 3 or led to a change in study medication. Serious Adverse Events (SAE) by International Council for Harmonization (ICH) criteria were excluded as they contributed to the primary safety outcome measure.&#xD;
Severity grading was based on DAIDS AE Grading Table, Corrected Version 2.1.&#xD;
A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Prematurely Discontinued HCV Study Medications</measure>
    <time_frame>From at least 22 weeks and up to 76 weeks from treatment initiation</time_frame>
    <description>Since there were no planned clinic visits during the 12 week study medication period, the last dose of study treatment was self-reported by participants, and recorded at the SVR evaluation visit at 24 weeks. Premature treatment discontinuation was defined when the self-reported final dose date was &lt;11 weeks (&lt;77 days) after the date of initial dose (accounting for any reported treatment holds). Participants discontinuing study follow up without information about completion of HCV study medications were counted as having prematurely discontinued medications.&#xD;
A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HIV-1-infection</condition>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>MINMON 24 weeks with SOF/VEL 12 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir/Velpatasvir (SOF/VEL)</intervention_name>
    <description>400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.</description>
    <arm_group_label>MINMON 24 weeks with SOF/VEL 12 Weeks</arm_group_label>
    <other_name>Epclusa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Minimal Monitoring (MINMON) Strategy</intervention_name>
    <description>MINMON Strategy:&#xD;
No pre-treatment HCV genotyping&#xD;
Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry&#xD;
No scheduled on-treatment laboratory monitoring or clinic visits&#xD;
Remote contact with participants at week 4 and week 22</description>
    <arm_group_label>MINMON 24 weeks with SOF/VEL 12 Weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Active Hepatitis C (HCV) infection, defined by HCV RNA &gt;1000 international units&#xD;
             (IU/mL) within 35 days prior to study entry&#xD;
&#xD;
          -  HCV treatment naïve&#xD;
&#xD;
          -  Liver disease staged as either non-cirrhotic (Fibrosis-4 (FIB-4) Score &lt;3.25) or&#xD;
             compensated cirrhotic (FIB-4 Score ≥3.25 and Child-Turcotte-Pugh (CTP) ≤Score 6)&#xD;
             within 35 days prior to study entry&#xD;
&#xD;
          -  HIV-1 negative, or HIV-1 positive with either a) Non-efavirenz containing&#xD;
             antiretroviral therapy (ART) started at least 14 days prior to study entry with plasma&#xD;
             HIV-1 RNA &lt;400 copies/mL within 90 days prior to study entry or b) not taking ART and&#xD;
             CD4+ cell count &gt;350 cells/uL within 90 days prior to study entry&#xD;
&#xD;
          -  The following laboratory values obtained within 35 days prior to study entry:&#xD;
&#xD;
               -  Albumin &gt;3.0 g/L&#xD;
&#xD;
               -  Hemoglobin &gt;8.0 g/dL for women; &gt;9.0 g/dL for men&#xD;
&#xD;
               -  Platelet count &gt;50,000/mm^3&#xD;
&#xD;
               -  Calculated creatinine clearance (CrCl) &gt;30 mL/min&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) &lt;10 times the upper limit of the normal range&#xD;
                  (ULN)&#xD;
&#xD;
               -  Alanine transaminase (ALT) &lt;10 times the ULN&#xD;
&#xD;
               -  Total bilirubin &lt;1.5 times the ULN for participants not on atazanavir (ATV); &lt;3&#xD;
                  times the ULN for participants on ATV&#xD;
&#xD;
               -  International normalized ratio (INR) &lt;1.5 times the ULN&#xD;
&#xD;
          -  For females of reproductive potential, a negative serum or urine pregnancy test within&#xD;
             48 hours prior to study entry&#xD;
&#xD;
          -  All participants of reproductive potential must have agreed not to participate in&#xD;
             conception process (e.g., active attempt to become pregnant or to impregnate, sperm&#xD;
             donation, in vitro fertilization) while on study treatment and for 6 weeks after&#xD;
             stopping study treatment&#xD;
&#xD;
          -  If participating in sexual activity that could lead to pregnancy, the all participants&#xD;
             of reproductive potential had to agree to use at least one reliable methods of&#xD;
             contraception while on study treatment and for 6 weeks after stopping study treatment&#xD;
&#xD;
          -  Participants who were not of reproductive potential were eligible without requiring&#xD;
             the use of contraceptives.&#xD;
&#xD;
          -  Life expectancy &gt;12 months&#xD;
&#xD;
          -  Ability and willingness to be contacted remotely&#xD;
&#xD;
          -  Ability and willingness of participant to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive for hepatitis B virus (HBV) surface antigen&#xD;
&#xD;
          -  For cirrhotic participants, CTP score &gt;6 corresponding to Class B or C&#xD;
&#xD;
          -  Breastfeeding or pregnancy&#xD;
&#xD;
          -  Known allergy/sensitivity or any hypersensitivity to components of study drugs or&#xD;
             their formulation&#xD;
&#xD;
          -  Active drug or alcohol use or dependence and other conditions that, in the opinion of&#xD;
             the site investigator, would interfere with adherence to study requirements.&#xD;
&#xD;
          -  Acute or serious illness requiring systemic treatment and/or hospitalization within 35&#xD;
             days prior to study entry&#xD;
&#xD;
          -  For HIV positive participants, presence of active or acute AIDS-defining opportunistic&#xD;
             infections within 35 days prior to study entry&#xD;
&#xD;
          -  Any history of hepatic decompensation including ascites, spontaneous bacterial&#xD;
             peritonitis, hepatic encephalopathy, hepatorenal syndrome, and/or bleeding esophageal&#xD;
             varices&#xD;
&#xD;
          -  Use of prohibited medications within the past 14 days prior to study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Solomon, MBBS, PhD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS (31788)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California (1201)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-1079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS (601)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsd, Avrc Crs (701)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Aids Crs (801)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS (6101)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whitman Walker Health CRS (31791)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center CRS (5802)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS (2701)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS (2702)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University CRS (201)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (MGH) CRS (101)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hosp. ACTG CRS (107)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS (2101)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School Clinical Research Center CRS (31786)</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Chelsea CRS (7804)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Physicians and Surgeons CRS (30329)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Upton CRS (7803)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs (3201)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greensboro CRS (3203)</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS (2401)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS (2501)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS (2301)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. of the Univ. of Pennsylvania CRS (6201)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pittsburgh CRS (1001)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital ACTG CRS (2951)</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics (VT) CRS (3652)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Health and Wellness Center CRS (31443)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston AIDS Research Team CRS (31473)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao CRS (12201)</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>9043010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica Evandro Chagas (12101)</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21045</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico-AIDS CRS (5401)</name>
      <address>
        <city>San Juan</city>
        <zip>00931</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Clinical Research Unit (FAM-CUR) CRS (8950)</name>
      <address>
        <city>Cape Town</city>
        <state>West Cape</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (31802)</name>
      <address>
        <city>Bangkok</city>
        <state>Patumwan</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai University HIV Treatment CRS (31784)</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Clinical Research Centre (JCRC) (12401)</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>Uganda</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables</url>
    <description>DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1</description>
  </link>
  <link>
    <url>http://rsc.niaid.nih.gov/clinical-research-sites/manual-expedited-reporting-adverse-events-daids</url>
    <description>Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual), Version 2.0, January 2010</description>
  </link>
  <link>
    <url>http://blast.ncbi.nlm.nih.gov/Blast.cgi</url>
    <description>NIH. BLAST® Basic Local Alignment Search Tool. US National Library of Medicine, National Center for Biotechnology Information, NIH; 2021</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <results_first_submitted>May 21, 2021</results_first_submitted>
  <results_first_submitted_qc>June 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 16, 2021</results_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03512210/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03512210/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03512210/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from October 2018 to July 2019 at 38 sites in Brazil, South Africa, Thailand, Uganda, and the United States.</recruitment_details>
      <pre_assignment_details>There was no randomization in this study. Enrollment from sites located in the United States was restricted to 132 participants. Enrollment of participants having compensated cirrhosis was limited to no more than 80 participants, and enrollment of people living with HIV was limited to no more than 200 participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MINMON 24 Weeks With SOF/VEL 12 Weeks</title>
          <description>Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks&#xD;
Sofosbuvir/Velpatasvir (SOF/VEL): 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.&#xD;
Minimal Monitoring (MINMON) Strategy: MINMON Strategy:&#xD;
No pre-treatment HCV genotyping&#xD;
Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry&#xD;
No scheduled on-treatment laboratory monitoring or clinic visits&#xD;
Remote contact with participants at week 4 and week 22</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="400"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who enrolled into study and received first dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>MINMON 24 Weeks With SOF/VEL 12 Weeks</title>
          <description>Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks&#xD;
Sofosbuvir/Velpatasvir (SOF/VEL): 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.&#xD;
Minimal Monitoring (MINMON) Strategy: MINMON Strategy:&#xD;
No pre-treatment HCV genotyping&#xD;
Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry&#xD;
No scheduled on-treatment laboratory monitoring or clinic visits&#xD;
Remote contact with participants at week 4 and week 22</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="399"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" lower_limit="37" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>20 to 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 to 69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 to 79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80+ years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="289"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uganda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender Identity</title>
          <description>Persons identifying across the transgender spectrum includes endorsement of any gender identities that do not match sex assigned at birth including transgender, genderqueer, gender variant or gender non-conforming, and other gender self-identities.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Cisgender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transgender Spectrum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-infection Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>HIV-1 infection absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV-1 infection present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cirrhosis Status</title>
          <description>Cirrhosis present defined as Fibrosis-4 (FIB-4) Score &gt;= 3.25 and cirrhosis absent is defined as FIB-4 Score &lt;3.25</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Cirrhosis present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cirrhosis absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA</title>
          <units>Log10 IU/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.1" lower_limit="5.6" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV Genotype</title>
          <description>Genotypes determined via Sanger sequencing of a short (~325 base pair) fragment sequence of the NS5B region and phylogenetic determination of genotype using Basic Local Alignment Search Tool (NIH BLAST; 2021). Specimen from 3 participants did not provide results and are listed as 'Unknown Genotype'.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Genotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Self Reported History of Substance Use</title>
          <description>History of substance use is defined as any current or previous usage of any of the following on the WHO ASSIST questionnaire at study entry: amphetamines, hallucinogens, cocaine, opioids, or sedatives. Current use is defined as use at least once in the past three months prior to study entry.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Currently</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previously</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virologic Response 12 (SVR12)</title>
        <description>SVR12 was defined as plasma HCV RNA less than the lower limit of quantification (LLOQ) from the earliest sample drawn at least 22 weeks following study treatment initiation (i.e. at a visit scheduled at least 10 weeks after scheduled end of study treatment). Participants without any HCV RNA result at least 22 weeks after treatment initiation will be considered as having HCV RNA greater than the LLOQ.&#xD;
LLOQ was defined as &lt;15 IU/mL for results tested at USA centralized testing laboratory Quest using the &quot;Roche COBAS® HCV Quantitative nucleic acid test for use on the COBAS® 6800/8800&quot; assays for quantitation (and detection) of HCV, and &lt;12 IU/mL for results tested at regional international labs using &quot;Abbott RealTime HCV&quot; assay for quantitation (and detection) of HCV.&#xD;
A two-sided 95%, confidence interval was calculated for this percentage using the Wilson (score) method.</description>
        <time_frame>From at least 22 weeks and up to 76 weeks from treatment initiation</time_frame>
        <population>Participants who enrolled and received first dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>MINMON 24 Weeks With SOF/VEL 12 Weeks</title>
            <description>Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks&#xD;
Sofosbuvir/Velpatasvir (SOF/VEL): 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.&#xD;
Minimal Monitoring (MINMON) Strategy: MINMON Strategy:&#xD;
No pre-treatment HCV genotyping&#xD;
Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry&#xD;
No scheduled on-treatment laboratory monitoring or clinic visits&#xD;
Remote contact with participants at week 4 and week 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response 12 (SVR12)</title>
          <description>SVR12 was defined as plasma HCV RNA less than the lower limit of quantification (LLOQ) from the earliest sample drawn at least 22 weeks following study treatment initiation (i.e. at a visit scheduled at least 10 weeks after scheduled end of study treatment). Participants without any HCV RNA result at least 22 weeks after treatment initiation will be considered as having HCV RNA greater than the LLOQ.&#xD;
LLOQ was defined as &lt;15 IU/mL for results tested at USA centralized testing laboratory Quest using the &quot;Roche COBAS® HCV Quantitative nucleic acid test for use on the COBAS® 6800/8800&quot; assays for quantitation (and detection) of HCV, and &lt;12 IU/mL for results tested at regional international labs using &quot;Abbott RealTime HCV&quot; assay for quantitation (and detection) of HCV.&#xD;
A two-sided 95%, confidence interval was calculated for this percentage using the Wilson (score) method.</description>
          <population>Participants who enrolled and received first dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="92.4" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Occurrence of Serious Adverse Events According to International Council for Harmonization (ICH) Criteria</title>
        <description>Serious adverse events (SAEs) as defined by ICH guidelines.&#xD;
A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method.</description>
        <time_frame>From treatment initiation to 28 weeks</time_frame>
        <population>Participants who received first dose of study medication and had at least one post-entry evaluation for adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>MINMON 24 Weeks With SOF/VEL 12 Weeks</title>
            <description>Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks&#xD;
Sofosbuvir/Velpatasvir (SOF/VEL): 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.&#xD;
Minimal Monitoring (MINMON) Strategy: MINMON Strategy:&#xD;
No pre-treatment HCV genotyping&#xD;
Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry&#xD;
No scheduled on-treatment laboratory monitoring or clinic visits&#xD;
Remote contact with participants at week 4 and week 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Occurrence of Serious Adverse Events According to International Council for Harmonization (ICH) Criteria</title>
          <description>Serious adverse events (SAEs) as defined by ICH guidelines.&#xD;
A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method.</description>
          <population>Participants who received first dose of study medication and had at least one post-entry evaluation for adverse events.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="397"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.1" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One Unplanned Clinic Visit Prior to SVR12 Evaluation</title>
        <description>According to the study minimal monitoring intervention, there were no planned clinic visits prior to study week 24, when SVR12 was scheduled to be evaluated. An unplanned clinic visit was defined as an in-clinic visit occurring from treatment initiation to up to week 22.&#xD;
A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method.</description>
        <time_frame>From treatment initiation to 22 weeks</time_frame>
        <population>Participants who enrolled and received first dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>MINMON 24 Weeks With SOF/VEL 12 Weeks</title>
            <description>Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks&#xD;
Sofosbuvir/Velpatasvir (SOF/VEL): 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.&#xD;
Minimal Monitoring (MINMON) Strategy: MINMON Strategy:&#xD;
No pre-treatment HCV genotyping&#xD;
Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry&#xD;
No scheduled on-treatment laboratory monitoring or clinic visits&#xD;
Remote contact with participants at week 4 and week 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Unplanned Clinic Visit Prior to SVR12 Evaluation</title>
          <description>According to the study minimal monitoring intervention, there were no planned clinic visits prior to study week 24, when SVR12 was scheduled to be evaluated. An unplanned clinic visit was defined as an in-clinic visit occurring from treatment initiation to up to week 22.&#xD;
A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method.</description>
          <population>Participants who enrolled and received first dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="2.3" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Occurrence of One or More Non-serious, Grade &gt;= 3 Adverse Event (AE), or Treatment Limiting AE.</title>
        <description>AEs included all primary diagnoses, primary signs/symptoms, and primary laboratory abnormalities that either had severity grade ≥ 3 or led to a change in study medication. Serious Adverse Events (SAE) by International Council for Harmonization (ICH) criteria were excluded as they contributed to the primary safety outcome measure.&#xD;
Severity grading was based on DAIDS AE Grading Table, Corrected Version 2.1.&#xD;
A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method.</description>
        <time_frame>From treatment initiation to 28 weeks</time_frame>
        <population>Participants who received first dose of study medication and had at least one post-entry evaluation for adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>MINMON 24 Weeks With SOF/VEL 12 Weeks</title>
            <description>Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks&#xD;
Sofosbuvir/Velpatasvir (SOF/VEL): 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.&#xD;
Minimal Monitoring (MINMON) Strategy: MINMON Strategy:&#xD;
No pre-treatment HCV genotyping&#xD;
Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry&#xD;
No scheduled on-treatment laboratory monitoring or clinic visits&#xD;
Remote contact with participants at week 4 and week 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Occurrence of One or More Non-serious, Grade &gt;= 3 Adverse Event (AE), or Treatment Limiting AE.</title>
          <description>AEs included all primary diagnoses, primary signs/symptoms, and primary laboratory abnormalities that either had severity grade ≥ 3 or led to a change in study medication. Serious Adverse Events (SAE) by International Council for Harmonization (ICH) criteria were excluded as they contributed to the primary safety outcome measure.&#xD;
Severity grading was based on DAIDS AE Grading Table, Corrected Version 2.1.&#xD;
A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method.</description>
          <population>Participants who received first dose of study medication and had at least one post-entry evaluation for adverse events.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="397"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5.1" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Prematurely Discontinued HCV Study Medications</title>
        <description>Since there were no planned clinic visits during the 12 week study medication period, the last dose of study treatment was self-reported by participants, and recorded at the SVR evaluation visit at 24 weeks. Premature treatment discontinuation was defined when the self-reported final dose date was &lt;11 weeks (&lt;77 days) after the date of initial dose (accounting for any reported treatment holds). Participants discontinuing study follow up without information about completion of HCV study medications were counted as having prematurely discontinued medications.&#xD;
A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method.</description>
        <time_frame>From at least 22 weeks and up to 76 weeks from treatment initiation</time_frame>
        <population>Participants who enrolled into study and received first dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>MINMON 24 Weeks With SOF/VEL 12 Weeks</title>
            <description>Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks&#xD;
Sofosbuvir/Velpatasvir (SOF/VEL): 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.&#xD;
Minimal Monitoring (MINMON) Strategy: MINMON Strategy:&#xD;
No pre-treatment HCV genotyping&#xD;
Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry&#xD;
No scheduled on-treatment laboratory monitoring or clinic visits&#xD;
Remote contact with participants at week 4 and week 22</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Prematurely Discontinued HCV Study Medications</title>
          <description>Since there were no planned clinic visits during the 12 week study medication period, the last dose of study treatment was self-reported by participants, and recorded at the SVR evaluation visit at 24 weeks. Premature treatment discontinuation was defined when the self-reported final dose date was &lt;11 weeks (&lt;77 days) after the date of initial dose (accounting for any reported treatment holds). Participants discontinuing study follow up without information about completion of HCV study medications were counted as having prematurely discontinued medications.&#xD;
A two-sided, 95% confidence interval was calculated for the percentage using the Wilson (score) method.</description>
          <population>Participants who enrolled into study and received first dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.4" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From treatment initiation to study completion at week 72. The week 72 window was extended for participants who completed SVR evaluations and registered to Step 2 to October 31, 2020 for US sites and to February 28, 2021 for non-US sites in response to COVID-19, up to a maximum of 110 weeks. Study follow up is complete but post-PCD data are under review and are excluded. AE summaries will be updated after database lock.</time_frame>
      <desc>For participants who received first dose of SOF/VEL and had at least one post-entry evaluation for AEs. Post-entry, all signs/symptoms, diagnoses, or abnormal laboratory findings new in onset or aggravated in severity or frequency from the baseline condition and meeting any of the following criteria were reported: ≥ Grade 3, led to change in SOF/VEL regardless of grade, or met expedited AE or ICH SAE guidelines. The DAIDS AE Grading Table (Correct V2.1) and Expedited AE Manual (V2.0) were used.</desc>
      <group_list>
        <group group_id="E1">
          <title>MINMON 24 Weeks With SOF/VEL 12 Weeks</title>
          <description>Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks&#xD;
Sofosbuvir/Velpatasvir (SOF/VEL): 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.&#xD;
Minimal Monitoring (MINMON) Strategy: MINMON Strategy:&#xD;
No pre-treatment HCV genotyping&#xD;
Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry&#xD;
No scheduled on-treatment laboratory monitoring or clinic visits&#xD;
Remote contact with participants at week 4 and week 22</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Acute right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Persistent depressive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder depressive type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gilbert's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal loss of weight</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tongue neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute lung injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ACTG Clinicaltrials.gov Coordinator</name_or_title>
      <organization>ACTG Network Coordinating Center, Social and Scientific Systems, a DLH Holdings Company</organization>
      <phone>301-628-3348</phone>
      <email>ACTGCT.gov@fstrf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

